Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 6Phase 1/2 4Phase 3 3Phase NA 1Phase 2/3 1

Status

Completed 3

Sponsor Class

NIH 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 109Radiotherapy 106Fluorouracil 76Doxorubicin 74Carboplatin 71Etoposide 67Cisplatin 67Vincristine 66Paclitaxel 58Chemotherapy, Adjuvant 53Leucovorin 47Specimen Handling 43Cytarabine 42Magnetic Resonance Spectroscopy 38Methotrexate 37Dexamethasone 33Taxes 31Bevacizumab 31Peripheral Blood Stem Cell Transplantation 30Gemcitabine 30Filgrastim 30Docetaxel 30Tamoxifen 28Melphalan 28Immunoglobulin G 25Epirubicin 25Disulfides 25Oxaliplatin 24Daunorubicin 24Prednisone 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × NIH × oblimersen × Clear all
NCT00016263 2014-01-06

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

National Cancer Institute (NCI)

Phase 3 Completed
Dermatologic

Melanoma

NCT00017602 2014-01-06

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00024440 2014-01-06

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡